Abstract:Changjin Wang, 1, &ast Xiaolu Hu, 1, 2, &ast Songyuan Luo, 1, &ast Yinghao Sun, 1 Bangyuan Yang, 1 Shengneng Zheng, 3 Jiaohua Chen, 1 Ming Fu, 1 Ruixin Fan, 4 Jie Li, 1 Jianfang Luo 1, 2 1 Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; 2 School of Medicine South China University of Technology, Guangzhou, People's Republic of China; 3 Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China; 4 Department of Cardiac Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jie Li; Jianfang Luo, Department of Cardiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, &num96 Dongchuan Road, Yuexiu District, Guangzhou, Guangdong, 510080, People's Republic of China, Tel +86-20-83827812, Fax +86-20-83875453, Email ; Purpose: In mixed aortic valve disease (MAVD), the results of transcatheter aortic valve replacement (TAVR) are conflicting. There is limited data on the outcomes of TAVR in patients with bicuspid aortic valve (BAV) and MAVD. The objective of this study is to compare outcomes after TAVR in BAV patients with MAVD and predominant aortic stenosis (PAS). Patients and Methods: Patients with BAV who underwent TAVR between January 2016 and April 2023 were included. The primary outcome was device success. The secondary endpoints were periprocedural mortality and other complications as defined by the Valve Academic Research Consortium-3 (VARC-3). Propensity score matching was used to minimize potential confounding. Results: A total of 262 patients were included in this study, 83 of whom had MAVD. The median age was 72 years, and 55.7% were male. The baseline comorbidity risk files were comparable between the two groups. Patients with MAVD had more mitral regurgitation, tricuspid regurgitation and pulmonary hypertension, larger annular and left ventricular outflow tract dimensions, and more severe calcification than PAS. In the unmatched population, MAVD patients had similar device success rate (69.9% vs 79.9%, P =0.075) and 30-day mortality (3.6% vs 3.4%, P =1) compared to PAS. Propensity score matching resulted in 66 patient pairs. Device success rate were still comparable in the matched population. Other clinical outcomes, including stroke, bleeding (type 2– 4), major vascular complications, acute kidney injury (stage 2– 4) and permanent pacemaker implantation, were comparable between the two groups. Multivariable logistic regression analysis did not show MAVD to be an independent negative predictor of device success. At one year, survival was similar between patients with MAVD and those with PAS. Conclusion: For the bicuspid valve, patients with MAVD had a more challenging anatomy. MAVD patients associated with comparable 30-day clinical outcomes after TAVR compared to PAS patients in patients with BAV. Keywords: transcatheter aortic valve replacement, mixed aortic valve disease, bicuspid aortic valve, device success, propensity score match The indications for transcatheter aortic valve replacement (TAVR) have been expanded from a high surgical risk to a low surgical risk. 1–3 The trend towards TAVR in younger and lower-risk patients has led to an increase in the number of BAV patients encountered by cardiac teams. 4 In previous studies, the outcome of TAVR in patients with BAV was comparable to that in patients with tricuspid valve. 5,6 Mixed aortic valve disease (MAVD), a combination of AS and moderate or severe aortic regurgitation (AR), was not uncommon in practice. 7 Moderate to severe AR was observed in 3% to 15% of patients with BAV treated with TAVR. 5,8 Due to pressure and volume overload, MAVD is more aggressive than isolated aortic valve lesions and is associated with worse clinical outcomes. 9,10 MAVD is currently managed according to the predominant lesion and the underlying surgical risk. 11,12 However, in patients with MAVD, the results of TAVR were mixed. 13–16 In a retrospective study analysing 1133 patients (MAVD, n=688), patients with MAVD who underwent TAVR had a lower 3-year mortality rate compared with patients with AS al -Abstract Truncated-

Treatment strategies for mixed aortic valve disease in nonelderly patients

Moderate mixed aortic valve disease -evaluation, treatment and prognosis of patients referred to heart valve center

[Catheter-based and surgical treatment for aortic valve diseases]

Lifetime Management of Adolescents and Young Adults with Congenital Aortic Valve Disease

Update of Transcatheter Valve Treatment

Treatment options for isolated aortic valve insufficiency: a review

Managing the patient undergoing transcatheter aortic valve replacement with ongoing mitral regurgitation

Lifetime Management for Aortic Stenosis: Strategy and Decision Making in the Current Era

How to approach aortic valve disease in the elderly: a 25-year retrospective study

Transcatheter aortic valve replacement for bicuspid aortic valve disease: does conventional surgery have a future?

Current Surgical Strategies and Techniques of Aortic Valve Diseases in Children

Long-term outcomes following aortic valve replacement in bioprosthetic vs mechanical valves

TAVR as an Alternative to SAVR for Pure Native Aortic Regurgitation

Should Mitral Valve Replacement Age Guidelines Be Lowered Due to Better Bioprosthetic Mitral Valve Durability?

Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?

Mechanical or biological prosthesis for aortic valve replacement in patients aged 45 to 74 years

Mixed aortic valve disease: association with paravalvular leak and reduced survival after transcatheter aortic valve replacement

Patient and procedure selection for the prevention of prosthesis-patient mismatch following aortic valve replacement

Treating the patients in the 'grey-zone' with aortic valve disease: a comparison among conventional surgery, sutureless valves and transcatheter aortic valve replacement

Assess the Outcomes of Transcatheter Aortic Valve Replacement in Bicuspid Valve with Mixed Disease versus Predominant Aortic Stenosis

Transcatheter Aortic Valve Implantation to Treat Degenerated Aortic, Mitral and Tricuspid Bioprosthesis